The relationship between the thyroid and pregnancy is one of the clearest examples of how maternal endocrine physiology must adapt to support a new biological compartment, the fetoplacental unit, without compromising maternal homeostasis. Pregnancy increases the requirement for thyroid hormones and iodine, substantially alters the dynamics of transport proteins, and introduces placental signals capable of mimicking the action of TSH. For this reason, simply applying interpretative criteria used outside pregnancy may lead to diagnostic errors, particularly in mild conditions or during the early stages.
From a clinical perspective, thyroid dysfunctions during pregnancy are relevant because they affect both maternal outcomes, including gestational hypertension, preeclampsia, arrhythmias, heart failure and obstetric complications, and fetal and neonatal outcomes, including growth restriction, preterm birth, pregnancy loss, and fetal and neonatal thyroid dysfunction. A significant proportion of the risk derives not only from overt disease but also from the interaction between thyroid autoimmunity, reduced functional reserve, and the increased hormonal requirement typical of the first trimester, when the fetus largely depends on maternal thyroid hormones for neurocognitive development.
Pregnancy modifies thyroid function through three main drivers: the increase in thyroxine-binding globulin (TBG), the thyrotropic stimulation mediated by human chorionic gonadotropin (hCG), and changes in iodine availability. The estrogen-dependent increase in TBG, caused by greater hepatic synthesis and reduced clearance due to sialylation, increases the protein-bound fraction of T4 and T3. Consequently, to maintain an unchanged biologically active free fraction, the thyroid must increase hormone production. This adaptation can make total hormone measurements potentially misleading when interpreted using non-pregnancy-specific reference ranges, while free hormone measurements require caution because analytical interference becomes more pronounced precisely when binding proteins change.
During the first trimester, hCG reaches high concentrations and can activate the TSH receptor, causing a physiological reduction in TSH in many pregnancies and, occasionally, a mild increase in FT4. The magnitude of the TSH reduction depends on the hCG peak, individual receptor sensitivity, and thyroid reserve. In hyperemesis gravidarum or multiple pregnancy, this effect is more pronounced and transient gestational thyrotoxicosis may develop, which differs from autoimmune hyperthyroidism in prognosis and therapeutic management.
At the same time, pregnancy increases iodine requirements for several reasons: increased glomerular filtration with greater urinary iodine loss, transplacental transfer of iodine to the fetus, and increased maternal thyroid hormone synthesis. In areas with borderline iodine availability or in women with insufficient intake, these factors may reveal a pre-existing vulnerability, promoting subclinical hypothyroidism, overt hypothyroidism, or goiter. In iodine-sufficient populations, thyroid enlargement is often modest, whereas in iodine-deficient settings it may become more pronounced, with consequences for biochemical control and gland volume.
A central element is the timing of fetal dependence on maternal thyroid hormones. During the first weeks, before full maturation of the fetal hypothalamic-pituitary-thyroid axis, the fetus relies substantially on maternal T4 transferred through the placenta, which is locally converted into T3 within target tissues. The placenta expresses specific deiodinases and transporters that regulate this transfer and protect the fetus from excessive exposure to active hormones, but these systems do not eliminate the risk when the mother has overt hypothyroidism or antibodies capable of crossing the placenta and directly modulating fetal thyroid function.
These considerations explain why pregnancy requires a dedicated interpretative approach. It is not merely a matter of altered reference ranges, but a new endocrine equilibrium in which the thyroid set point, transport proteins, iodine, and placental signals interact. Appropriate clinical management begins with recognition of this physiology, because every therapeutic or monitoring decision must take into account a system that changes over time, trimester by trimester, and that may change again after delivery because of immune rebound and the end of hCG-mediated stimulation.
In practical terms, pregnancy transforms a static thyroid assessment into a dynamic evaluation. Clinical history, the presence of autoimmunity, iodine status, and the longitudinal pattern of laboratory parameters must be integrated, avoiding decisions based on a single isolated value. This is particularly important in women with known autoimmune thyroiditis, previous thyroid surgery, radioiodine treatment, significant nodular disease, or previous hyperthyroidism, all of which may limit functional reserve and the response to increased hormonal demand.
Finally, physiological adaptation is not uniform among individuals. Genetic and environmental variability, iodine intake, age, body mass index, use of interfering medications, and differences between laboratory methods increase heterogeneity. For this reason, modern management emphasizes the need for population-specific and method-specific reference intervals and, when these are unavailable, pragmatic strategies based on cautious adjustments and close follow-up in at-risk groups.
The first clinical step is to determine which tests should be used and how they should be interpreted. During pregnancy, TSH remains the cornerstone test, but its meaning changes, particularly during the first trimester, when hCG-mediated stimulation may physiologically lower its concentration. FT4 is essential for distinguishing physiologically low TSH from clinically significant hormone excess and for identifying central hypothyroidism or conditions in which TSH is not a reliable marker. However, FT4 measurement may be problematic because of analytical interference. Consequently, when robust methods are unavailable, some guidelines recommend the use of TT4 with appropriate corrections or method-specific reference intervals, while maintaining consistency by using the same laboratory throughout pregnancy.
The most important practical principle is to use pregnancy-specific reference ranges, ideally established locally according to population, iodine status, and analytical method. When these are unavailable, some recommendations propose alternative approaches: avoiding the automatic application of standard non-pregnancy cutoffs and preferring contextual assessment, with repeat testing after a short interval when results are borderline. In many situations, particularly mild disorders, the temporal trend has greater decision-making value than a single result, provided that the patient is clinically stable.
The assessment should include testing for autoimmunity when this changes the pre-test probability and clinical management. Positivity for thyroid peroxidase antibodies (TPOAb) or thyroglobulin antibodies (TgAb) identifies an autoimmune background and increases the risk of progression to hypothyroidism during pregnancy and the postpartum period. When autoimmune hyperthyroidism is suspected, TSH receptor antibodies (TRAb) are central because they correlate with disease activity and, more importantly, cross the placenta and may induce fetal and neonatal thyroid dysfunction. TRAb measurement therefore also has fetal relevance, rather than merely reflecting maternal disease.
When TSH is elevated, the distinction between subclinical and overt hypothyroidism depends on FT4, and the therapeutic decision integrates trimester, symptoms, medical history, pre-pregnancy levothyroxine dose, antibody status, and obstetric comorbidities. When TSH is suppressed or very low, the distinction between gestational thyrotoxicosis and autoimmune hyperthyroidism relies on clinical history, physical findings, FT4 and FT3, TRAb, and, when present, orbitopathy or a hypervascular goiter. Thyroid scintigraphy is contraindicated during pregnancy, and clinical reasoning therefore replaces diagnostic tools available outside pregnancy.
A frequently underestimated issue concerns iatrogenic interference. Iron and calcium, commonly used in obstetric supplementation, reduce levothyroxine absorption when taken close to the dose. Antacids, sucralfate, and some high-fiber supplements may have similar effects. In hyperthyroidism, beta-blockers have a rationale for symptomatic treatment but require attention to dose and duration, whereas exposure to amiodarone is uncommon during pregnancy but, when present, creates considerable diagnostic and therapeutic complexity because of its iodine content and direct effects on thyroid hormone metabolism.
The evaluation strategy should be structured in levels. In women without risk factors or symptoms, the most controversial issue is universal screening versus targeted screening. In many settings, a selective risk-based approach is used, but the definition of risk must be broad and include a personal history of thyroid dysfunction, goiter or nodules, autoimmunity, type 1 diabetes, other autoimmune diseases, previous miscarriage or preterm birth, infertility or assisted reproductive techniques, advanced maternal age, obesity, exposure to iodine or radiation, and use of medications that interfere with thyroid function. In these patients, early evaluation, ideally during the first trimester or before conception, is the most effective strategy for identifying reduced reserve before it becomes clinically relevant.
In practical terms, pregnancy also requires laboratory discipline: the same method and laboratory should be used whenever possible, blood sampling immediately after levothyroxine administration should be avoided, sampling time should be standardized, and testing should be repeated at predefined intervals during periods of greater physiological instability, particularly after dose adjustments or during the first two trimesters. This reduces apparent fluctuations and allows safer titration, which is the primary objective in patients already receiving replacement therapy or antithyroid treatment.
Finally, assessment cannot be limited to biochemical testing. Physical examination should focus on goiter, signs of thyrotoxicosis, hyporeflexia, skin changes, heart rate, blood pressure, and the presence of murmurs. Together with obstetric evaluation and fetal growth assessment, these findings complement laboratory interpretation and determine the level of urgency. During pregnancy, the threshold for concern is lower because timing is critical. Overt hypothyroidism that is not treated early cannot be completely corrected retrospectively in terms of neurodevelopmental effects, while uncontrolled hyperthyroidism may rapidly compromise maternal cardiovascular compensation and placental perfusion.
Adequate iodine availability is a prerequisite for supporting the increased synthesis of thyroid hormones during pregnancy. Major health authorities emphasize that requirements are higher than in non-pregnant women and that prevention of iodine deficiency is an integral component of maternal and fetal protection. Physiologically, iodine deficiency reduces the thyroid gland’s ability to increase T4 production precisely when maternal requirements are higher, promoting increased TSH, thyroid hyperplasia, and possible hypothyroidism, with potential effects on pregnancy and fetal development. The concern is greater in areas with borderline iodine availability and in women with autoimmune thyroiditis, whose thyroid reserve is already reduced.
The most effective population-level preventive strategy is iodine prophylaxis through iodized salt, but actual adherence and effective intake vary across countries, regions, and dietary habits. In settings where iodized salt coverage is not universal or dietary intake is insufficient, international recommendations support targeted supplementation during pregnancy and breastfeeding to ensure adequate intake. When indicated, supplementation is generally based on potassium iodide at doses compatible with the recommended total daily intake, also considering any prenatal multivitamins already being taken.
From a clinical perspective, nutritional intervention is not neutral for every patient. In women with thyroid functional autonomy, such as a toxic nodule or toxic multinodular goiter, an excessive increase in iodine intake may promote iodine-induced hyperthyroidism. During pregnancy, these scenarios are less common than autoimmune forms, but they should be considered in patients with pre-existing nodular goiter, suppressed TSH before pregnancy, or a history of non-autoimmune thyrotoxicosis. Even in women with autoimmune thyroiditis, the goal is to correct deficiency rather than create excess, because excessive iodine may worsen dysfunction in some settings and interfere with thyroid homeostasis.
In addition to iodine, other micronutrients and dietary habits interact indirectly with the thyroid. Selenium contributes to deiodinase activity and thyroid antioxidant functions, but routine supplementation is not universally recommended and should be considered cautiously, particularly because the primary objective remains optimization of thyroid control with specific therapy when required. The key principle is to avoid a supplement-centered approach and maintain an evidence-based strategy: iodine when indicated, correction of documented deficiencies, and attention to pharmacological interference that reduces levothyroxine absorption.
A highly relevant practical issue concerns the obstetric co-prescription of iron and calcium. These supplements are often necessary, but when taken at the same time as levothyroxine they reduce its absorption and may simulate an apparent need for a higher dose that is actually iatrogenic. Prevention consists of separating the timing of administration and providing clear counselling, because adherence during pregnancy is influenced by the number of tablets and by nausea. Biochemical assessment should always consider these variables before repeated and unnecessary dose increases are made.
Finally, prevention includes clinical education regarding acute iodine exposure, such as iodinated contrast media. During pregnancy, contrast administration is limited to situations of genuine necessity, but when used it may produce a significant iodine load with potential effects on the maternal and fetal thyroid. In these circumstances, the safest approach is preventive planning with thyroid assessment and post-exposure follow-up, particularly if the patient has known thyroid disease or risk factors. The aim is not to create unnecessary concern, but to reduce predictable adverse events during a period in which the window for intervention is narrow.
Hypothyroidism during pregnancy is clinically relevant because the increased requirement for T4 may make a previously adequate thyroid reserve insufficient and because the first trimester represents a critical window for fetal development. Overt forms are associated with an increased risk of maternal and fetal complications and require prompt treatment. Subclinical forms raise questions regarding definition and treatment thresholds because their association with adverse outcomes depends on the degree of TSH elevation, the presence of autoimmunity, and the clinical context, while data from intervention studies are not uniform. Guidelines therefore recommend a stratified approach, with a stronger tendency toward treatment when significantly elevated TSH coexists with positive TPOAb or when there is an adverse obstetric history.
In women already receiving levothyroxine before conception, pregnancy often requires an early dose increase because the rise in TBG and greater tissue demand begin during the first weeks. The practical principle is that a patient who is well controlled before pregnancy may rapidly become under-replaced if she continues the same dose. Modern management involves prompt dose adjustment after a positive pregnancy test or during the earliest part of the first trimester, followed by close monitoring. This is particularly important in women without a thyroid gland after thyroidectomy or with reduced reserve following radioiodine ablation or advanced thyroiditis, because they cannot increase endogenous production in response to pregnancy-related stimulation.
In women newly diagnosed during pregnancy, replacement therapy should be initiated according to disease severity. In overt hypothyroidism, the goal is to normalize FT4 rapidly and bring TSH into an appropriate trimester-specific range without delay. In subclinical hypothyroidism, the decision integrates autoimmunity, TSH concentration, symptoms, comorbidities, and obstetric risk. A key point is that titration must be rapid but controlled. During pregnancy, slow correction is not useful when the objective is to protect an early developmental window, but prolonged overshooting into iatrogenic hyperthyroidism is also unsafe because it may increase tachycardia, weight loss, and cardiovascular stress.
Monitoring is generally scheduled every 4 weeks during dose adjustment or throughout the first two trimesters and is then modified according to stability. TSH and FT4 are the main tools, with the important exception that TSH is unreliable in central hypothyroidism, where the target shifts to FT4 in the upper-normal range for the assay. Every dose change should be followed by reassessment at an interval consistent with the half-life of levothyroxine and the dynamics of TSH. Interpretation must always include adherence, administration technique, and interactions with obstetric supplements.
Clinically, hypothyroidism may mimic common pregnancy symptoms such as fatigue, weight gain, and constipation, making biochemical assessment essential. Physical examination may identify relative bradycardia, dry skin, edema, or goiter, but diagnosis is primarily laboratory-based. In autoimmune cases with goiter, ultrasonography may be useful for documenting a pattern compatible with chronic thyroiditis and characterizing any nodules, but it is not necessary for deciding on replacement therapy when the biochemical diagnosis is clear.
An often overlooked issue is postpartum management. After delivery, the increased dose requirement diminishes and in many patients the dose can be reduced toward the pre-pregnancy level, but the timing and magnitude depend on the cause of hypothyroidism and on whether postpartum thyroiditis develops. In women with autoimmune thyroiditis, the postpartum period carries a high risk of fluctuations, and planned testing prevents both symptomatic hypothyroidism and iatrogenic hyperthyroidism if the dose is not readjusted. Breastfeeding is not a contraindication to levothyroxine and requires therapeutic continuity because maternal stability is part of the overall safety of both mother and infant.
Thyrotoxicosis during pregnancy is not a single entity. The first clinical step is to distinguish autoimmune hyperthyroidism, particularly Graves disease, from hCG-mediated gestational thyrotoxicosis. The latter is more common during the first trimester, is often associated with severe nausea or hyperemesis, and tends to resolve as hCG concentrations decline. In this setting, antithyroid therapy is generally unnecessary and can be avoided in favor of supportive measures and symptomatic control. In contrast, Graves disease is mediated by TRAb, may persist or worsen, and requires a strategy to control hormone excess and reduce maternal and fetal risk.
Maternal risks of uncontrolled hyperthyroidism include tachyarrhythmias, worsening of underlying cardiac disease, weight loss, and heart failure, in addition to increased obstetric risk. Fetal risks include growth restriction, prematurity and, when TRAb concentrations are elevated, fetal and neonatal thyroid dysfunction. This is the most pregnancy-specific aspect of the disease: stimulating or blocking antibodies directed against the TSH receptor cross the placenta and can directly modulate the fetal thyroid, particularly during the second half of pregnancy, when placental permeability and fetal thyroid function are greater. Measurement and follow-up of TRAb therefore have prognostic value and guide the intensity of fetal surveillance.
Antithyroid treatment during pregnancy is based on thionamides, with strict attention to gestational timing. The principle is to achieve biochemical control with the lowest effective dose, maintaining FT4 within the upper-normal range or slightly above the method-specific reference range, while avoiding iatrogenic fetal hypothyroidism. During the first trimester, propylthiouracil is generally preferred to reduce the risk of methimazole-associated embryopathy, whereas during the second and third trimesters many protocols recommend switching to methimazole to reduce the risk of propylthiouracil-related hepatotoxicity. This decision should be individualized, documented, and accompanied by regular clinical and biochemical monitoring.
Beta-blockers may be useful for symptomatic control of tachycardia and tremor, but prolonged use at high doses is undesirable because of possible fetal effects. In practice, they are used as bridging treatment during the initial phase or during exacerbations, with dose and duration reduced as soon as thyroid control improves. Management of thyroid storm during pregnancy is a rare but extremely severe emergency requiring intensive multidisciplinary care, rapid control of hormone excess and its systemic consequences, and treatment of the precipitating trigger.
Thyroid surgery is an option in selected cases, including intolerance or inadequate response to medications, a persistent need for high doses, or a concomitant suspicion of malignancy. It is generally considered during the second trimester to minimize anesthetic and obstetric risks. Radioiodine is contraindicated during pregnancy because of fetal thyroid uptake and the risk of permanent fetal hypothyroidism. If radioiodine is planned postpartum, breastfeeding must be discontinued according to protocol-specific timelines, and the mother should be managed through a planned pathway that avoids impulsive decisions capable of compromising neonatal safety.
A clinically important issue is that Graves disease activity may improve during pregnancy because of immune modulation but can flare during the postpartum period. This has two implications. During pregnancy, antithyroid therapy may be reduced in patients whose disease improves, but vigilance is required after delivery, when autoimmune reactivation may be rapid. In addition, if the patient previously had Graves disease and was treated with radioiodine or surgery, TRAb may remain elevated even when she is euthyroid on replacement therapy, maintaining fetal risk. In these cases, antibody assessment and fetal surveillance remain necessary even in the absence of active maternal hyperthyroidism.
Thyroid autoimmunity, particularly TPOAb positivity, is common among women of reproductive age and does not necessarily imply thyroid dysfunction at the time of conception. However, it identifies reduced functional reserve and an increased risk of developing hypothyroidism during pregnancy, particularly when the increased hormonal requirement challenges an already partially impaired thyroid gland. From a prognostic perspective, numerous observational studies have associated antibody positivity with adverse obstetric outcomes, including pregnancy loss and preterm birth, but translating this association into a universal indication for levothyroxine in euthyroid women remains controversial. Randomized studies have not always produced consistent results, and the definition of euthyroidism during pregnancy depends on the reference ranges used.
The clinically established point is that women with autoimmunity have a greater risk of developing biochemical decompensation during pregnancy. In practical terms, a woman with positive TPOAb and TSH in the upper-normal or borderline range should be monitored more frequently because a progressive increase in TSH may occur rapidly. In addition, the postpartum period carries a risk of postpartum thyroiditis, which may present with an initial thyrotoxic phase followed by hypothyroidism and, in some cases, progress to permanent hypothyroidism. A history of pre-existing thyroid autoimmunity increases the likelihood of this course.
During preconception counselling and the first trimester, the objective is to reduce exposure to unrecognized hypothyroidism. This approach does not necessarily require treatment of every antibody-positive woman, but it does require a structured surveillance strategy. The decision to treat subclinical hypothyroidism is more favorable in the presence of autoimmunity, particularly when TSH exceeds thresholds considered clinically significant by guidelines, when there is a history of infertility or pregnancy loss, or when pregnancy is achieved through assisted reproductive techniques. In this setting, hormonal changes induced by ovarian stimulation may amplify thyroid hormone requirements and make reserve insufficient in women with autoimmunity.
It is important to distinguish what is biologically plausible from what has been demonstrated as a therapeutic benefit. The association between autoimmunity and complications may reflect a direct role of inflammation and immune dysregulation in implantation and placentation or may represent a marker of subclinical endocrine vulnerability. In either case, reasonable management integrates targeted screening, monitoring, and prompt treatment when dysfunction emerges. Unnecessary treatment carries the risk of shifting the patient toward iatrogenic hyperthyroidism, particularly when targets are not pregnancy-specific and therapy is continued without reassessment.
In summary, thyroid autoimmunity is a powerful risk signal that modifies the clinical strategy. It does not automatically indicate active disease, but it makes precision medicine based on trends, pregnancy-specific biochemical targets, and attention to the postpartum period essential. During the postpartum period, many patients who remained completely stable throughout pregnancy may develop symptoms that are incorrectly attributed solely to puerperal fatigue or psychological distress if thyroid testing is not planned.
Pregnancy may make pre-existing nodular disease more evident because of increased vascularity and greater clinical attention to the neck, but it should not automatically lead to aggressive procedures. Assessment of a thyroid nodule during pregnancy is based on clinical history, physical examination, and thyroid ultrasonography with ultrasound risk stratification. Fine-needle aspiration is generally considered safe during pregnancy and can be performed when indicated by the ultrasound profile and nodule size, with the objective of distinguishing benign nodules from suspicious lesions. The rationale is to avoid unjustified diagnostic delays when the probability of carcinoma is significant, while also preventing overdiagnosis and overtreatment during a physiologically complex period.
When differentiated thyroid carcinoma is diagnosed during pregnancy, management is guided by tumor biology, stage, growth rate, and gestational timing. Many low-risk papillary carcinomas grow slowly and can be monitored until after delivery without worsening oncological prognosis, particularly when there are no signs of local invasion or significant lymph node metastases. In these cases, the priority is to ensure obstetric safety and maternal stability, with surgery scheduled after delivery when appropriate. If signs of aggressive behavior, rapid growth, or compressive involvement are present, surgery may be considered during pregnancy, typically in the second trimester, when the relative risks are lower than during the first and third trimesters.
Levothyroxine therapy in this context has two purposes: maintaining maternal euthyroidism and, in selected cases, reducing thyrotropic stimulation. During pregnancy, however, marked TSH suppression is not the standard objective because iatrogenic hyperthyroidism may have maternal and fetal consequences. The most prudent approach is optimized control of thyroid function, with individualized targets and monitoring that considers both oncological and obstetric requirements. After delivery, the oncological strategy can be realigned with standard protocols through complete assessment and, when indicated, radioiodine, which remains contraindicated during pregnancy and incompatible with active breastfeeding.
Risk communication is a fundamental practical issue. The diagnosis of a thyroid nodule or carcinoma during pregnancy may generate intense anxiety and prompt rushed decisions. Evidence-based medicine supports an approach that clearly distinguishes what is urgent for maternal and fetal safety from what can be planned without loss of oncological efficacy. This requires multidisciplinary endocrinological, obstetric, and surgical assessment, explicit definition of timing, and documented ultrasound monitoring when surveillance until the postpartum period is selected.
Thyroid treatment during pregnancy requires a balance between efficacy and fetal safety. Levothyroxine is considered safe and represents the standard replacement treatment for hypothyroidism, with the objective of maintaining an adequate thyroid hormone signal. Optimal management is not limited to dosage but also includes administration technique and prevention of interactions. The most frequent problem is reduced absorption caused by concomitant intake of iron, calcium, or other supplements commonly prescribed during pregnancy. Separating the timing of administration and educating the patient significantly reduce instability and the apparent need for repeated dose increases.
In the treatment of hyperthyroidism, thionamides are effective but require careful use because of maternal and potential fetal risks. The clinical principle is to maintain control with the lowest necessary dose, avoiding progression toward hypothyroidism. The choice between propylthiouracil and methimazole depends on trimester and risk profile. During the first trimester, propylthiouracil is generally preferred to reduce specific teratogenic risks associated with methimazole. From the second trimester onward, many protocols favor methimazole to reduce the risk of propylthiouracil-related hepatotoxicity. This strategy requires monitoring and documentation because switching medications is not automatic, but a clinical decision based on hormonal control, required dose, and tolerability.
Beta-blockers have a symptomatic role but should be used judiciously. They are generally most useful as short-term treatment at the beginning of antithyroid therapy or during exacerbations to control tachycardia and tremor. Prolonged high-dose use is undesirable and requires individual assessment. The obstetric context is also relevant. In a patient with hyperemesis and gestational thyrotoxicosis, management of nausea and hydration may reduce the need for thyroid-specific medication, avoiding unnecessary exposure.
Radioiodine is contraindicated during pregnancy and represents a non-negotiable safety issue. Exposure carries a high risk to the fetal thyroid, particularly beyond the first trimester, when the fetal thyroid can take up iodine. Even when radioiodine therapy is administered shortly before conception, reproductive planning with protocol-recommended waiting periods is required, and the patient should be followed during stabilization of thyroid function and TRAb concentrations, which may increase after radioiodine and continue to have implications for a subsequent pregnancy.
An important issue concerns iodinated contrast media and iodine-rich medications. Excess iodine may alter maternal and potentially fetal thyroid function. During pregnancy, these exposures should be limited to indispensable indications and accompanied by follow-up. When they are necessary, the safest approach is to anticipate the problem through thyroid assessment and a monitoring strategy during the following weeks, because abnormalities may emerge after a delay and be confused with nonspecific pregnancy symptoms.
Finally, pharmacological management must be divided into phases. The first trimester is the most delicate period for embryonic and fetal development and for hCG-mediated TSH variability. The second and third trimesters require stabilization and prevention of complications, with particular attention to fetal surveillance when TRAb concentrations are elevated or the mother requires significant doses of antithyroid medication. The postpartum period requires dose reassessment because the end of pregnancy removes the physiological drivers that increased requirements and reactivates immune dynamics capable of destabilizing thyroid function. Throughout this sequence, safety derives from consistency: clear objectives, scheduled monitoring, and measured adjustments.
Fetal surveillance becomes specifically thyroid-oriented when there is a genuine risk of fetal thyroid dysfunction or when maternal thyroid status may alter placental perfusion and growth. The main scenarios are autoimmune hyperthyroidism with elevated TRAb, antithyroid treatment at significant doses, and, more rarely, exposure to substantial iodine loads. The most typical mechanism is the transplacental passage of TRAb, which may stimulate or block the fetal TSH receptor, causing fetal hyperthyroidism or hypothyroidism, respectively. The probability increases during the second half of pregnancy, when the fetal thyroid is more functionally active and the placenta allows greater immunoglobulin transfer.
Surveillance is based on the integration of maternal data and fetal signs. On the maternal side, serial TRAb measurement and biochemical control with FT4 and FT3 guide risk stratification. On the fetal side, obstetric ultrasonography may identify indirect signs of thyroid dysfunction, including fetal goiter, persistent tachycardia, growth abnormalities, hydrops, or alterations in amniotic fluid volume. These findings are not specific and must be interpreted within the clinical context, but when present in a mother with elevated TRAb or receiving antithyroid therapy, they increase the probability of genuine fetal dysfunction and require adjustment of management.
An essential principle is that the goal is not to normalize maternal biochemical parameters at any cost, but to protect the fetus by avoiding pharmacological excess. Thionamides cross the placenta and may induce fetal hypothyroidism if overdosed. For this reason, the maternal target generally consists of FT4 within the upper-normal range or slightly above it, reducing the risk of fetal hypothyroidism. In complex cases, management may require careful balancing between control of maternal symptoms and fetal protection, with close monitoring and multidisciplinary decision-making.
During the neonatal period, the risk mainly concerns pregnancies with elevated TRAb or maternal hyperthyroidism during gestation. The newborn may develop neonatal thyrotoxicosis, often presenting with tachycardia, irritability, poor weight gain and, in severe cases, heart failure. Diagnosis requires neonatal biochemical and clinical assessment and rapid management. Neonatal hypothyroidism may also occur when blocking antibodies predominate or exposure to antithyroid medications has been high. A neonatal surveillance program, with advance notification of the neonatal care team, is an integral part of managing at-risk pregnancies.
It should be emphasized that most women with well-controlled thyroid disease do not require special fetal surveillance beyond standard obstetric practice. The objective is to identify categories in which risk is genuine and intervene proportionately. The safest medical approach avoids both excessive medicalization and underestimation of situations in which antibodies or therapy may directly affect the fetus. The key is stratification based on autoimmunity, disease activity, and treatment intensity, with written monitoring plans for pregnancy and the postpartum period.
The postpartum period represents a phase of rapid endocrine and immune transition. The end of pregnancy removes hCG-mediated stimulation and reduces the estrogenic effect on TBG, once again altering the balance between total and free hormones. At the same time, the immune system, which tends toward a state of relative tolerance during pregnancy, may rebound toward greater autoimmune activity. This makes the postpartum period a time of high risk for Graves disease exacerbation and postpartum thyroiditis, particularly in women with pre-existing thyroid autoimmunity.
Postpartum thyroiditis often has a biphasic course: an initial thyrotoxic phase caused by the release of preformed hormones following follicular damage, followed by a hypothyroid phase due to depletion of reserves and reduced secretory capacity. The thyrotoxic phase may be mistaken for puerperal anxiety or insomnia, and the hypothyroid phase for postpartum depression or fatigue, if targeted testing is not performed. Treatment depends on the phase. During the thyrotoxic phase, thionamides are generally ineffective because the mechanism is not hormone overproduction, whereas beta-blockers may be useful for symptoms. During the hypothyroid phase, levothyroxine may be indicated when symptoms are significant, hypothyroidism is marked, or the patient requires optimal stability. Reassessment over time is necessary because some patients recover thyroid function, while others progress to permanent hypothyroidism, particularly when TPOAb concentrations are strongly positive.
Breastfeeding is compatible with levothyroxine and, in most cases, with appropriate management of hyperthyroidism, but requires therapeutic coordination. Thionamides may also be used during breastfeeding at doses considered compatible with safety, with clinical monitoring and an approach that minimizes the effective dose. Planning is essential because a woman who leaves pregnancy with perfect control may deteriorate within a few weeks, and early intervention reduces the impact on maternal health and on her ability to manage breastfeeding and sleep.
In women receiving replacement therapy, the levothyroxine dose can often be reduced after delivery toward the pre-pregnancy dose, but the reduction should not be automatic. If the woman has autoimmune hypothyroidism and the dose was increased during pregnancy, a reduction is often appropriate, but the risk of postpartum thyroiditis requires scheduled testing. In women without a thyroid gland or with stable permanent hypothyroidism, the reduction may be more predictable, but it should still be guided by TSH and FT4 rather than by standard protocols alone. Postpartum surveillance is therefore an essential component of quality of care rather than an incidental detail.
Finally, the postpartum phase has implications for subsequent pregnancies. A history of postpartum thyroiditis increases the risk of recurrence and permanent hypothyroidism, and a history of Graves disease may be followed by similar reactivation patterns. A modern strategy includes counselling for reproductive planning, preconception assessment of thyroid function, and definition of a monitoring plan before the next conception, particularly when the woman experienced significant instability during a previous postpartum period.